Humbert O., Riedinger J.M., Vrigneaud J.M., Kanoun S., Digay-Cochet I., Berriolo-Riedinger A., Toubeau M., Depardon E., Lasserre M., Tisserand S.,Fumoleau P., Brunotte F., Cochet A. 18F-FDG PET derived tumor blood flow changes after one cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer. J Nucl Med. 2016 Apr 21.

Humbert O., Cochet A., Coudert B., Berriolo-Riedinger A., Kanoun S., Brunotte F., Fumoleau P. Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer. Oncologist. 2015, 20: 94-104.

Humbert O., Riedinger J. M., Charon-Barra C., Berriolo-Riedinger A., Desmoulins I., Lorgis V., Kanoun S., Coutant C., Fumoleau P., Cochet A., Brunotte F. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Clin. Cancer Res. 2015 Jun 30.

Maurizi L., Papa A.L., Dumont L., Bouyer F., Walker P., Vandroux D., Millot N. Influence of Surface Charge and Polymer Coating on Internalization and Biodistribution of Polyethylene Glycol-Modified Iron Oxide Nanoparticles. J Biomed Nanotechnol. 2015, 11(1): 126-36.

Bernhard Y., Collin B., Decreau R. A. Inter/Intramolecular Cherenkov Radiation Energy Transfer (CRET) From a Fluorophore With a Built-in Radionuclide. Chem. Commun. (Camb. ) 2014, 50: 6711-6713.!divAbstract

Humbert O., Berriolo-Riedinger A., Cochet A., Gauthier M., Charon-Barra C., Guiu S., Desmoulins I., Toubeau M., Dygai-Cochet I., Coutant C., Fumoleau P., Brunotte F. Prognostic Relevance at 5 Years of the Early Monitoring of Neoadjuvant Chemotherapy Using (18)F-FDG PET in Luminal HER2-Negative Breast Cancer. Eur. J. Nucl. Med. Mol. Imaging. 2014, 41: 416-427.

Humbert O., Cochet A., Riedinger J. M., Berriolo-Riedinger A., Arnould L., Coudert B., Desmoulins I., Toubeau M., Dygai-Cochet I., Guiu S., Coutant C., Fumoleau P., Brunotte F. HER2-Positive Breast Cancer: 18F-FDG PET for Early Prediction of Response to Trastuzumab Plus Taxane-Based Neoadjuvant Chemotherapy. Eur. J. Nucl. Med. Mol. Imaging 2014, 41: 1525-1533.

Cochet A., Dygai-Cochet I., Riedinger J. M., Humbert O., Berriolo-Riedinger A., Toubeau M., Guiu S., Coutant C., Coudert B., Fumoleau P., Brunotte F. 18F-FDG PET/CT Provides Powerful Prognostic Stratification in the Primary Staging of Large Breast Cancer When Compared With Conventional Explorations. Eur. J. Nucl. Med. Mol. Imaging. 2014, 41: 428-437.

Walker P, Provent P, Tizon X, Créhange G, Duchamp O, Brunotte F, Genne P: In-vivo metabolic characterization of healthy prostate and orthotopic prostate cancer in rats using proton magnetic resonance spectroscopy at 4.7 T. Acta Radiol. 2013, 54(1): 121-6.

Cochet A., Pigeonnat S., Khoury B., Vrigneaud J. M., Touzery C., Berriolo-Riedinger A., Dygai-Cochet I., Toubeau M., Humbert O., Coudert B., Fumoleau P., Arnould L., Brunotte F. Evaluation of Breast Tumor Blood Flow With Dynamic First-Pass 18F-FDG PET/CT: Comparison With Angiogenesis Markers and Prognostic Factors. J. Nucl. Med. 2012, 53: 512-520.

Humbert O., Berriolo-Riedinger A., Riedinger J. M., Coudert B., Arnould L., Cochet A., Loustalot C., Fumoleau P., Brunotte F. Changes in 18F-FDG Tumor Metabolism After a First Course of Neoadjuvant Chemotherapy in Breast Cancer: Influence of Tumor Subtypes. Ann. Oncol. 2012, 23: 2572-2577.

Moreau M., Raguin O., Vrigneaud J. M., Collin B., Bernhard C., Tizon X., Boschetti F., Duchamp O., Brunotte F., Denat F. DOTAGA-Trastuzumab. A New Antibody Conjugate Targeting HER2/Neu Antigen for Diagnostic Purposes. Bioconjug. Chem. 2012, 23: 1181-1188.

Cochet A., Quilichini G., Dygai-Cochet I., Touzery C., Toubeau M., Berriolo-Riedinger A., Coudert B., Cottin Y., Fumoleau P., Brunotte F. Baseline Diastolic Dysfunction As a Predictive Factor of Trastuzumab-Mediated Cardiotoxicity After Adjuvant Anthracycline Therapy in Breast Cancer. Breast Cancer Res. Treat. 2011, 130 : 845-854.

Crehange G, Maingon P, Gauthier M, Parfait S, Cochet A, Mirjolet C, Bonnetain F, Cormier L, Brunotte F, Walker P. Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year. Int J Radiat Oncol Biol Phys. 2011, 81(4): e407-13.